Morgan Stanley Durect Corp Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.43 - $5.9 $55,256 - $758,173	-128,504 Reduced 44.6%	159,609 $93,000
Q2 2022 Oct 27, 2022	BUY	$0.38 - $0.64 $54,366 - $91,564	143,069 Added 98.64%	288,113 $137,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.64 $54,366 - $91,564	143,069 Added 98.64%	288,113 $137,000
Q1 2022 Oct 27, 2022	SELL	$0.55 - $0.98 $78,687 - $140,207	-143,069 Reduced 49.66%	145,044 $96,000
Q1 2022 May 13, 2022	SELL	$0.55 - $0.98 $39,063 - $69,604	-71,025 Reduced 32.87%	145,044 $96,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $67,401 - $98,105	74,890 Added 53.05%	216,069 $213,000
Q3 2021 Nov 15, 2021	BUY	$1.21 - $1.61 $170,826 - $227,298	141,179 New	141,179 $182,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $216M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.